One week from today, on May 10th, MRKR reports earnings.
Estimate is -$0.17.
If it is substantially worse than that, then you may?, possibly?, get one final chance to buy MRKR in the low 5's.
After that it should be a slow, steady, slow climb higher and higher until news (yes, even in the absence of news).
If (whenever that is) we get definitively great FDA trials news (it will come), it will jump up big as shorts will be forced to cover.
Up till now, the shorts have ruled the battlefield because every time they shorted more and more, there was NO substantial buying to reciprocate against it to act as a counterbalance.
Once we get that great FDA news and the price jumps up, YES, YES, the shorts who covered will jump back in and short at the then much higher price, BUT the difference will be, THEN there WILL BE substantial buying to reciprocate against it to act as a counterbalance, and the climb higher and higher will continue.
To anybody who has been worried about the stock price decline over the last few months, stop worrying, it was not due to fundamentals, it was due to shorters.
To anybody who got scared out and sold recently, buy back in so you're not kicking yourself is the ass come the end of 2019 and beyond, because the more beyond we go, the more you're going to be mad at yourself for selling and not holding.
I don't want to ramble, but no brainers don't come along very often.
In 1991, anybody who understood Qualcomm's CDMA technology compared to the then current TDMA or GSM technology KNEW it was a no brainer that CDMA will take over the world.
I think MRKR's MultiTAA technology versus CAR-T is a similar no brainer.
No matter what you compare it to, individual CAR-T, off the shelf CAR-T, CRISPR, RNAI, MDNA, Talon, Zinc fingers, etc., when you compare all of the positives and all of the negatives (price, risk, time, side effects, etc.) concerning all, I think MultiTAA is a no brainer that will capture a substantial share of the market for several cancer indications.
